Elekta (OTCMKTS:EKTAY) Raised to “Hold” at Zacks Research

Elekta (OTCMKTS:EKTAY) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Elekta Trading Up 0.5%

Shares of OTCMKTS EKTAY opened at $4.99 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $5.32 and a two-hundred day simple moving average of $5.86. The firm has a market cap of $1.84 billion, a PE ratio of -31.16 and a beta of 1.01. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93.

Elekta (OTCMKTS:EKTAY) last issued its earnings results on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The business had revenue of $521.00 million during the quarter. Analysts expect that Elekta will post 0.43 earnings per share for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.